Research Report Update - Q3 Report
​SYGNIS AG is a life sciences company listed in the Prime Standard of the German Stock Exchange (Deutsche Börse). The company focuses on the development and marketing of innovative molecular biology technologies in the NGS (next-generation sequencing) sector. Its most important products currently on the market are TruePrimeTM (DNA amplification) and SunScriptTM (translating RNA into DNA), which are sold both through their own marketing and through non-exclusive sales partnerships. Other products (e.g. DNA amplification through liquid biopsy) will shortly be launched to enter into high-volume markets (e.g. hospitals). SYGNIS AG has acquired Expedeon Holdings Ltd. through a capital increase in kind. This expanded the product range into the field of proteomics, the second most important sector in the field of life science. Important synergy effects are arising especially in the sales area, as Expedeon has a direct sales network in the most important life sciences markets worldwide as USA, UK and Asia.
Die GBC AG mit Sitz in Augsburg ist eines der führenden bankenunabhängigen Investmenthäuser in Deutschland und erfahrener Emissionsexperte für den deutschen Mittelstand.
Die GBC AG kennt als eigentümergeführtes Unternehmen die Bedürfnisse des deutschen Mittelstandes im Finanzierungsbereich und ist ein unabhängiger und verlässlicher Partner bei allen Fragestellungen rund um den Kapitalmarkt.
In der GBC Gruppe bietet die GBC AG Unternehmensanalysen & Research, Kapitalmarkt- & Finanzierungsberatungen sowie Kapitalmarktkonferenzen.
Die GBC Kapital GmbH ergänzt die Leistungen in der Gruppe um das Corporate Finance in den Bereichen Platzierung & Vermittlung von Anleihen und Aktien
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.